Form 4: AbbVie SVP, Controller Kevin K. Buckbee Reports Stock Transactions
SEC Form 4 Filing
AbbVie's SVP, Controller Kevin K. Buckbee, reports the acquisition and disposal of AbbVie common stock and stock options on February 26, 2025.
Summary
- On February 26, 2025, Kevin K. Buckbee, SVP, Controller of AbbVie Inc., reported transactions involving AbbVie's common stock.
- Buckbee sold 2,684 shares at $203.4 per share and 16,260 shares at a weighted average price of $203.41, with prices ranging from $203.39 to $203.48.
- He also exercised options to acquire 9,738 shares at $93.5 and 6,522 shares at $105.92.
- Following these transactions, Buckbee directly owns 11,496 shares of common stock.
- Buckbee also owns options to purchase 2,373 shares at $93.5 and 2,794 shares at $105.92.
- Additionally, Buckbee transferred 1,150 shares to his former spouse due to a domestic relations order.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company executives. It's typical for executives to have stock options as part of their compensation and to periodically exercise them and sell shares.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The exercise of stock options and subsequent sale of shares is a common practice among executives in publicly traded companies, including pharmaceutical giants like Pfizer, Johnson & Johnson, and Merck.
- The reported transactions are within the normal range of executive stock activity and do not appear unusual compared to industry benchmarks.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of shares outstanding.
- The transfer of shares to a former spouse could be of interest to stakeholders, but is unlikely to have a material impact.
Key Dates
| Date | Description |
|---|---|
| 02/20/2021 | Date exercisable for options on 9,738 shares. |
| 02/18/2022 | Date exercisable for options on 6,522 shares. |
| 02/26/2025 | Date of the reported transactions (stock sales and option exercises). |
| 02/19/2030 | Expiration date for options on 9,738 shares. |
| 02/17/2031 | Expiration date for options on 6,522 shares. |
| 02/28/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.